C. Gaujoux-viala, L. Gossec, A. Cantagrel, M. Dougados, B. Fautrel et al., Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde, Revue du Rhumatisme, vol.81, issue.4, pp.303-312, 2014.

Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson et al., Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.48, issue.6, pp.681-695, 2008.

C. E. St, C. L. Wagner, A. A. Fasanmade, B. Wang, T. Schaible et al., The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum. juin, vol.46, issue.6, pp.1451-1460, 2002.

D. Ternant, T. Bejan-angoulvant, C. Passot, D. Mulleman, and G. Paintaud, Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis, Clinical Pharmacokinetics, vol.54, issue.11, pp.1107-1123, 2015.

K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. C. Kapetanovic et al., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ? inhibitor infliximab, Arthritis & Rheumatism, vol.54, issue.12, pp.3782-3789, 2006.

D. Mazilu, D. Opri?, C. Gainaru, M. Iliuta, N. Apetrei et al., Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment, BioMed Research International, vol.2014, pp.1-8, 2014.

G. J. Wolbink, Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-707, 2005.

F. Siljehult, L. Ärlestig, C. Eriksson, and S. Rantapää-dahlqvist, Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis, Scandinavian Journal of Rheumatology, vol.47, issue.5, pp.345-350, 2018.

F. Cornillie, S. B. Hanauer, R. H. Diamond, J. Wang, K. L. Tang et al., Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial, Gut, vol.63, issue.11, pp.1721-1727, 2014.

D. Ternant, E. Ducourau, A. Perdriger, A. Corondan, B. Le-goff et al., Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.78, issue.1, pp.118-128, 2014.

C. Plasencia, T. Jurado, A. Villalba, D. Peitedado, M. T. Casla et al., Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions, Frontiers in Medicine, vol.2, 2015.

J. Méric, D. Mulleman, E. Ducourau, F. Lauféron, D. C. Miow-lin et al., Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study, Therapeutic Drug Monitoring, vol.33, issue.4, pp.411-416, 2011.

R. Krzysiek, M. Breban, P. Ravaud, M. V. Prejean, J. Wijdenes et al., Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study, Arthritis & Rheumatism, vol.61, issue.5, pp.569-576, 2009.

A. Amiot, A. Hulin, M. Belhassan, C. Andre, C. Gagniere et al., Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission, Clinics and Research in Hepatology and Gastroenterology, vol.40, issue.1, pp.90-98, 2016.

A. Petitcollin, C. Brochard, L. Siproudhis, C. Tron, M. Verdier et al., Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De?Escalation in Adults With Inflammatory Bowel Diseases, Clinical Pharmacology & Therapeutics, vol.106, issue.3, pp.605-615, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02086789

N. Vande-casteele, M. Ferrante, G. Van-assche, V. Ballet, G. Compernolle et al., Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease, Gastroenterology, vol.148, issue.7, pp.1320-1329.e3, 2015.

B. J. Van-den-bemt, A. A. Den-broeder, G. Wolbink, A. Van-den-maas, Y. A. Hekster et al., The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.76, issue.6, pp.939-945, 2013.

M. Jani, H. Chinoy, R. B. Warren, C. E. Griffiths, D. Plant et al., Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis, The Lancet, vol.385, p.S48, 2015.

M. U. Rahman, I. Strusberg, P. Geusens, A. Berman, D. Yocum et al., Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1233-1238, 2007.

G. D?haens, S. Vermeire, G. Lambrecht, F. Baert, P. Bossuyt et al., Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn?s Disease, Gastroenterology, vol.154, issue.5, pp.1343-1351.e1, 2018.

T. Bejan?angoulvant, D. Ternant, F. Daoued, F. Medina, L. Bernard et al., Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis, Arthritis & Rheumatology, vol.69, issue.1, pp.108-113, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01980809

C. L. Krieckaert, S. C. Nair, M. T. Nurmohamed, C. J. Van-dongen, W. F. Lems et al., Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects, Annals of the Rheumatic Diseases, vol.74, issue.2, pp.361-368, 2013.

L. Martelli, P. Olivera, X. Roblin, A. Attar, and L. Peyrin-biroulet, Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review, Journal of Gastroenterology, vol.52, issue.1, pp.19-25, 2016.

R. F. Van-vollenhoven, How to dose infliximab in rheumatoid arthritis: new data on a serious issue, Annals of the Rheumatic Diseases, vol.68, issue.8, pp.1237-1239, 2009.

J. Laine, K. Puolakka, S. Jokiranta, K. Eklund, and M. Väkeväinen, Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers, Biologics: Targets and Therapy, p.67, 2016.

F. S. Velayos, J. G. Kahn, W. J. Sandborn, and B. G. Feagan, A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab, Clinical Gastroenterology and Hepatology, vol.11, issue.6, pp.654-666, 2013.

X. Roblin, A. Attar, M. Lamure, B. Savarieau, P. Brunel et al., Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab, Journal of Market Access & Health Policy, vol.3, issue.1, p.29229, 2015.

K. Lekpa, F. Farrenq, V. Claudepierre, and P. , Critères de réponse dans les spondylarthropathies : définition d'un répondeur, Rev Rhum Monogr. févr, vol.77, issue.1, pp.52-60, 2010.

C. Gaujoux-viala, Évaluation de l?activité de la polyarthrite rhumatoïde, Revue du Rhumatisme Monographies, vol.84, issue.4, pp.343-346, 2017.

D. Mulleman, J. Méric, G. Paintaud, E. Ducourau, C. Magdelaine-beuzelin et al., Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis, Arthritis Research & Therapy, vol.11, issue.6, p.R178, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00375858

A. Jamnitski, G. M. Bartelds, M. T. Nurmohamed, P. A. Van-schouwenburg, D. Van-schaardenburg et al., The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept, Annals of the Rheumatic Diseases, vol.70, issue.2, pp.284-288, 2010.

M. F. Pouw, C. L. Krieckaert, M. T. Nurmohamed, D. Van-der-kleij, L. Aarden et al., Key findings towards optimising adalimumab treatment: the concentration?effect curve, Annals of the Rheumatic Diseases, vol.74, issue.3, pp.513-518, 2013.

D. Dénarié, M. Rinaudo-gaujous, T. Thomas, S. Paul, and H. Marotte, Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab, Mediators of Inflammation, vol.2017, pp.1-7, 2017.

A. A. Suleiman, M. Minocha, A. Khatri, Y. Pang, and A. A. Othman, Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I?III Clinical Trials, Clinical Pharmacokinetics, vol.58, issue.10, pp.1309-1321, 2019.

J. Zochling, Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Sp, Arthritis Care & Research, vol.63, issue.S11, pp.S47-S58, 2011.

C. Heegaard, L. Dreyer, C. Egsmose, and O. R. Madsen, Test?retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints, Clinical Rheumatology, vol.32, issue.10, pp.1493-1500, 2013.